Raymond James Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22

Benzinga Newsdesk www.benzinga.com Negative 93.0%

Neg 93% Neu 0% Pos 0%

Raymond James analyst Sean McCutcheon maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $24 to $22.